title: Large vessel coronary vasospasm: diagnosis, natural history and treatment.
abstract: The diagnosis of coronary artery spasm is confirmed by angiography, for example, change in caliber of the coronary arteries plus evidence of ischemia. The prevalence and contribution of coronary artery spasm in the individual patient with symptoms of ischemic heart disease is not known and depends on how the condition is defined. The prognosis of patients with coronary artery spasm appears to depend on the presence or absence of severe coronary atherosclerosis, that is, those with severe disease have a worse prognosis. Nitrates should be used to initiate therapy in all patients with this problem. Intravenous nitrates have proven useful in patients whose symptoms are difficult to control and who require hospitalization. beta blockers used alone may be detrimental in patients with coronary artery spasm, but studies supporting the detrimental effects are few. The combination of nitrates, beta blockers and nifedipine has proved effective therapy for many patients with recurrent angina at rest, possibly related to coronary artery spasm. Several open-label and double-blind placebo control trials have shown that all of the calcium antagonists are effective short-term agents for patients with proven coronary artery spasm. When nifedipine was compared with isosorbide dinitrate in a randomized crossover, double-blind trial in patients with coronary artery spasm, both drugs were shown to be efficacious and neither was superior. The traditional alpha-blocking agents have not been shown to be an effective therapy, but a recent study of prazosin, a selective alpha blocker, revealed excellent results in patients whose conditions were resistant to therapy with traditional calcium blockers, beta blockers and, in 1 case, phenoxybenzamine.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: C R
authors.initials: CR
authors.lastname: Conti
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy / Q000601:surgery; D003329:Coronary Vasospasm / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D004110:Diltiazem / Q000627:therapeutic use; D004562:Electrocardiography; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D009543:Nifedipine / Q000627:therapeutic use; D009566:Nitrates / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D005343:Fibrinolytic Agents; D009566:Nitrates; D014700:Verapamil; D011464:Epoprostenol; D004110:Diltiazem; D009543:Nifedipine; D007548:Isosorbide Dinitrate; D001241:Aspirin; D011224:Prazosin